The FDA approved Genentech's Actemra, or tocilizumab, to treat patients age 2 and older with active systemic juvenile idiopathic arthritis, or Still's disease. Actemra is given alone or with methotrexate, the agency said. The drug originally was approved early last year for adults who respond poorly to tumor necrosis factor antagonists.

Related Summaries